These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34427028)

  • 1. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19.
    Passante M; Napolitano M; Dastoli S; Bennardo L; Fabbrocini G; Nisticò SP; Patruno C
    Dermatol Ther; 2021 Nov; 34(6):e15111. PubMed ID: 34427028
    [No Abstract]   [Full Text] [Related]  

  • 2. Real world evidence on treatment of chronic spontaneous urticaria with omalizumab: Preliminary data.
    Corrao S; Prestigiacomo MA; Angileri RG; Natoli G; Argano C
    Dermatol Ther; 2020 Jul; 33(4):e13458. PubMed ID: 32319167
    [No Abstract]   [Full Text] [Related]  

  • 3. Safely use of omalizumab during SARS-CoV-2 infection in patients with chronic spontaneous urticaria.
    Özdemir Ö; Dikici Ü
    J Cosmet Dermatol; 2023 Jan; 22(1):26-27. PubMed ID: 36448319
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on "Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab".
    Abdelmaksoud A; Goldust M; Vestita M
    Int J Dermatol; 2020 Nov; 59(11):1417-1418. PubMed ID: 32989738
    [No Abstract]   [Full Text] [Related]  

  • 5. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 6. Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab.
    Noshela Ghazanfar M; Thomsen SF
    Eur Ann Allergy Clin Immunol; 2017 Nov; 49(6):284-285. PubMed ID: 29249138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature.
    Passanisi S; Arasi S; Caminiti L; Crisafulli G; Salzano G; Pajno GB
    Dermatol Ther; 2020 Jul; 33(4):e13489. PubMed ID: 32358910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. It is never too late to treat chronic spontaneous urticaria with omalizumab: Real-life data from a multicenter observational study focusing on elderly patients.
    Martina E; Damiani G; Grieco T; Foti C; Pigatto PDM; Offidani A
    Dermatol Ther; 2021 Mar; 34(2):e14841. PubMed ID: 33527659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study.
    Abduelmula A; Georgakopoulos JR; Mufti A; Devani AR; Gooderham MJ; Hong CH; Jain V; Lansang P; Vender R; Prajapati VH; Yeung J
    J Cutan Med Surg; 2022; 26(3):319-320. PubMed ID: 34587789
    [No Abstract]   [Full Text] [Related]  

  • 10. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria.
    Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM
    Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
    Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J
    Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of at least 1-year use of omalizumab without interruption on relapse in patients with chronic spontaneous urticaria.
    Su O; Bahali AG; Onsun N
    Dermatol Ther; 2020 Nov; 33(6):e14192. PubMed ID: 32790183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of as-needed antihistamines in chronic spontaneous urticaria patients under omalizumab treatment.
    Türk M; Yılmaz İ; Nazik Bahçecioğlu S; Can P; Ertaş R; Kartal D; Çınar SL; Kocatürk E
    Dermatol Ther; 2021 Jan; 34(1):e14543. PubMed ID: 33190334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?
    Asero R
    Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis.
    Syrigos N; Grapsa D; Syrigou E
    Eur Ann Allergy Clin Immunol; 2017 Nov; 49(6):286-287. PubMed ID: 29249139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients.
    Ghazanfar MN; Sand C; Thomsen SF
    Br J Dermatol; 2016 Aug; 175(2):404-6. PubMed ID: 26972689
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
    Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
    Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of omalizumab in severe chronic spontaneous urticaria: Real life data from a Greek tertiary center.
    Kyriakou A; Trigoni A; Sotiriadis D; Patsatsi A
    Dermatol Ther; 2018 Nov; 31(6):e12739. PubMed ID: 30194796
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
    Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
    Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
    [No Abstract]   [Full Text] [Related]  

  • 20. Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?
    Konstantinou GN; Chioti AG; Daniilidis M
    Eur Ann Allergy Clin Immunol; 2016 Sep; 48(5):205-7. PubMed ID: 27608479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.